See Ace Laboratories, Inc at our new website: www.acelabSseattle.com

RSS feed

Ace Laboratories, Inc. Announces Hiring of Medical Director & Appointment of Traumatic Brain Injury Specialists to Scientific Advisory Board

RSS feed

The recent appointments of specialists in Traumatic Brain Injury expand Ace’s internal capabilities in neurovascular drug development.

http://www.biospace.com/news_story.aspx?StoryID=463457&full=1

Developing medical solutions for the United States Military serivce member & Department of Defense.

RSS feed

We are excited to share with you the facinating press overview of the labs that explore solutions to the United States Department of Defense warfighter’s needs in sleep deprivation & health. This communicates well how lack of sleep is a major readiness and health problem for those who United States Armed Forces, where putting the job off for tomorrow isn’t possible. We’ve been extremely impressed with Dr William “Scott” Killgore, and his work in traumatic brain injury and developing military solutions.

https://www.wired.com/2014/03/military-obsession-with-caffeine/

Reviving resveratrol

RSS feed

Reviving Resveratrol

Chemical & Engineering News
Volume 95 Issue 10 pp. 38-39
Issue Date: March 6, 2017

Red wine made the compound famous; now one supplement maker hopes ongoing human tests can bring new life to its business

http://cen.acs.org/articles/95/i10/Reviving-resveratrol.html

Ace Laboratories Appoints Inaugural Scientific And Clinical Advisory Board

RSS feed

Ace Laboratories Appoints Inaugural Scientific And Clinical Advisory Board

Ace Laboratories, Inc., an emerging innovator in translating basic research into the physiology of aging into clinical applications, announces the formation of its Scientific and Clinical Advisory Board. Ace Labs is currently developing a proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in the media as “the red wine molecule”. To augment the development of their lead formulation, AIC-101, the Company has assembled a world-class Scientific and Clinical Advisory Board comprised of leading resveratrol researchers and clinicians including:

Chair, James Smoliga, DVM, Ph.D, Associate Professor, Department of Physical Therapy, Department of Basic Pharmaceutical Sciences, High Point University, High Point, North Carolina

Dr. Joseph Baur, Ph.D, Assistant Professor, Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Dr. Marina Holz, Ph.D., Professor and the Doris and Ira Kukin Chair in Biology at Yeshiva University and Albert Einstein College of Medicine, New York, New York

Dr. R. Scott Turner, MD, Ph.D., Professor, Director of the Memory Disorders Program, Department of Neurology, Georgetown University, Washington, District Of Columbia

“We are elated to announce the formation of our stellar Scientific and Clinical Advisory Board and look forward to working with them to build an exciting new proprietary pharmaceutical pipeline,” said Chief Executive Officer Chip Jacob.

About Ace Laboratories Seattle

Ace Laboratories is focused on enhancing human health via the application of its proprietary technology to unlock the therapeutic potential of resveratrol. It plans to investigate AIC-101, its lead product candidate, in vascular and inflammatory indications such as Alzheimer’s disease and Mild to Moderate Traumatic Brain Injury/Concussion.
Resveratrol is a natural polyphenol found in red wine. It captured public interest in 2006 after a landmark study showed that it improved the health-span of rodents. In the decades since, a number of human clinical trials have demonstrated that resveratrol has potential to be helpful to patients with vascular and Alzheimer’s diseases, amongst other conditions associated with aging. However, the molecule’s large-scale potential has been constrained to date by poor oral bioavailability and dose-limiting gastrointestinal side effects. The Company’s management believes that its proprietary technology may effectively address these limitations.
Ace Labs is led by an experienced team including Chief Executive Officer Chip Jacob, Chief Technology Officer Otis Blanchard, Chairman Daniel Wilds, and Corporate Secretary Jim Johnston. The group brings more than a hundred years of collective drug development experience and has a successful working history together.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Ace Laboratories’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with funding, product commercialization and commercial operations, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Media Contact:
Chip Jacob
CEO
Ace Laboratories, Inc.
info(at)acelabseattle(dot)com

Ace Laboratories, Inc. Announces Licensing of Resveratrol Patents

RSS feed

http://www.biospace.com/news_story.aspx?StoryID=446076&full=1

SEATTLE, WA (PRWEB) FEBRUARY 07, 2017
Ace Laboratories, Inc. (http://www.Acelabseattle.com) today announced the execution of an exclusive license to methods and compositions related to trans-mucosal delivery of resveratrol. The company has assembled an experienced drug development team to develop the technology for pharmaceutical use in vascular and inflammatory indications.

Resveratrol, a natural polyphenol found in red wine, captured the public interest in 2006 after a landmark study showed it improved the health-span of rodents fed a high calorie diet. In the decade since, human clinical trials have demonstrated resveratrol has potential to be helpful to patients with vascular and Alzheimer’s diseases, amongst other conditions associated with aging. However, the molecule’s large-scale potential to improve human health has been constrained to date by poor oral bioavailability and dose-limiting gastrointestinal side effects.

Ace Laboratories’ lead product candidate, AIC-101, appears to circumvent resveratrol’s oral delivery problems by freeing the molecule to be absorbed directly into the bloodstream across the tissue in the mouth in a process known as buccal or oral trans-mucosal delivery. An early trial in human volunteers suggested this new delivery method allows more resveratrol to enter the bloodstream, while also being more rapidly absorbed than standard delivery methods.

In January 2017 Dr. R. Scott Turner and his team at Georgetown University published further results from a 119 patient Phase II dose escalation trial showing positive neurovascular effects of resveratrol in Alzheimer’s disease. High dose resveratrol improved the function of the blood brain barrier and led to reduced inflammation in the brains of Alzheimer’s patients, but also resulted in weight loss in the elderly population. “There are few drugs that target vascular tissues. The results of this trial lead us to believe that improved resveratrol delivery could have important implications for the treatment of neurovascular disease,” said Dr. James Smoliga, chair of Ace Laboratories Scientific advisory board.

Ace Laboratories plans to investigate AIC-101 in Alzheimer’s disease, Mild to Moderate Traumatic Brain Injury/Concussion, as a co-therapy in Erectile dysfunction, and in certain orphan diseases. The Company is led by an experienced team including Chief Executive Officer Chip Jacob, Chief Technology Officer Otis Blanchard, Chairman Daniel Wilds, and Corporate Secretary Jim Johnston. The group brings more than a hundred years of collective drug development experience and has a successful working history together. “We are excited to announce the formation of Ace Laboratories, Inc., and its licensed technology to unlock the potential of resveratrol. We look forward to continuing to build on our clinical pipeline in conjunction with our stellar network of university researchers,” said Chief Executive Officer Chip Jacob.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Ace Laboratories’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with funding, product commercialization and commercial operations, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Media Contact:
Chip Jacob
CEO
Ace Laboratories, Inc.
info(at)acelabseattle.com

Scientists Get Closer to Harnessing the Health Benefits of Red Wine

RSS feed

Lozenge shows potential as a novel delivery system: Study

RSS feed

Lozenge shows potential as a novel delivery system: Study

“Delivering resveratrol via a lozenge that dissolves in the mouth may increase the absorption of the red wine compound more than other dosage forms for absorption in the gut, according to new data.”

Get in touch

Powered by WordPress. Designed by WooThemes